Table 1.

Demographic information and mean visual acuity at baseline and 6, 12, 18, 24 and 36 months (the number of eyes with a measurement at each point is shown in parentheses). Data on treatment burden and the numbers and percentages of eyes switching treatment are also shown

	Anti-VEGF	Macular laser	Dexamethasone
Mean age at baseline	72.0	72.5	71.9
Gender (% male)	47.4	48.6	45.9
Baseline CF (%)	57 (1.3)	14 (2.2)	14 (2.1)
Baseline HM (%)	23 (0.6)	2 (0.3)	3 (0.4)
Mean VA in ETDRS letters (n)
At baseline	57.1 (3859)	62.3 (620)	53.1 (659)
At 6 months	65.9 (1598)	60.9 (110)	59.7 (188)
At 12 months	66.7 (1042)	63.2 (53)	57.6 (95)
At 18 months	66.6 (713)	60.8 (48)	56.1 (71)
At 24 months	67.2 (485)	56.4 (30)	59.3 (45)
At 36 months	68 (203)	50.1 (23)	62.9 (20)

anti-VEGF, anti-vascular endothelial growth factor; CF, counting fingers; HM, hand movement; VA, visual acuity.